相关实验视频

Updated: Jan 9, 2026

A Mouse Tumor Model of Surgical Stress to Explore the Mechanisms of Postoperative Immunosuppression and Evaluate Novel Perioperative Immunotherapies

A Mouse Tumor Model of Surgical Stress to Explore the Mechanisms of Postoperative Immunosuppression and Evaluate Novel Perioperative Immunotherapies

Published on: March 12, 2014

新辅助免疫治疗对瘤性乳腺癌手术术术后并发症的影响

Capucine Barjot¹, Thomas Gaillard¹, Romain-David Seban²

¹Department of Breast, Gynecology and Reconstructive Surgery, Institut Curie, 75005, Paris, France; Institut of Women Cancer, Institut Curie, Paris, France.

European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology

|December 1, 2025

概括

对三阴性乳腺癌 (TNBC) 进行化疗的新辅助 pembrolizumab 并没有显著增加术后并发症. 治疗后最佳的外科手术时间对于降低风险至关重要,特别是在免疫治疗中.

科学领域:

在瘤学瘤学.
手术瘤学手术瘤学
免疫治疗是一种免疫疗法.

背景情况:

新辅助药 pembrolizumab 加上化疗是治疗II-III期三阴性乳腺癌 (TNBC) 的标准.
对术后并发症的影响,特别是在瘤塑性或重建性手术后,尚不清楚.

研究的目的:

评估新辅助药布罗利祖马布与化疗对TNBC早期患者手术后并发症的影响.
确定影响并发症率的因素,包括手术时间和手术类型.

主要方法:

追溯性前后研究 (2019年1月 - 2023年5月),比较单独化疗 (CT) 与化疗加 pembrolizumab (CT+P) 组.
对术后并发症的分析,包括伤口愈合延迟,感染和亡.
单变量和多变量逻辑回归用于评估风险因素.

主要成果:

整体并发症率为15.7%,CT和CT+P组之间没有显著差异 (p=0.061).
在CT+P组中,伤口愈合的延迟更频繁 (10%对3.8%,p=0.031),但免疫治疗不是一个独立的风险因素 (OR 1.27,p=0.5).
手术时间 (治疗后<14天或>30天) 与并发症增加有关 (p=0.029),特别是在CT+P组.

结论:

新辅助药 pembrolizumab 在TNBC患者中没有显著提高术后并发症率.
与新辅助疗法相比,手术时间是影响手术结果的关键,可修改的因素.

关键词:

植入物植入物是一种植入物.新辅助剂布罗利祖马.瘤塑性手术是一项瘤塑性手术.术后并发症术后并发症三阴性乳腺癌是三阴性乳腺癌.

更多相关视频

Endoscopic Bilateral Nipple-sparing Mastectomy via a Single Axillary Incision with Immediate Pre-pectoral Implant-based Breast Reconstruction

Endoscopic Bilateral Nipple-sparing Mastectomy via a Single Axillary Incision with Immediate Pre-pectoral Implant-based Breast Reconstruction

Published on: May 17, 2024

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies

Published on: July 28, 2020

相关概念视频

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Cancer Vaccines

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...

Cancer Therapies

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...